antikor biopharma limited
antikor biopharma limited Company Information
Company Number
04170519
Next Accounts
Apr 2025
Industry
Other research and experimental development on natural sciences and engineering
Shareholders
ironwood citadel (ptc) limited
essex bio-investment limited
View AllGroup Structure
View All
Contact
Registered Address
montague house chancery lane, thrapston, northamptonshire, NN14 4LN
Website
www.antikor.co.ukantikor biopharma limited Estimated Valuation
Pomanda estimates the enterprise value of ANTIKOR BIOPHARMA LIMITED at £1.4m based on a Turnover of £1.1m and 1.29x industry multiple (adjusted for size and gross margin).
antikor biopharma limited Estimated Valuation
Pomanda estimates the enterprise value of ANTIKOR BIOPHARMA LIMITED at £9.9m based on an EBITDA of £1.7m and a 5.88x industry multiple (adjusted for size and gross margin).
antikor biopharma limited Estimated Valuation
Pomanda estimates the enterprise value of ANTIKOR BIOPHARMA LIMITED at £17.7m based on Net Assets of £8.3m and 2.13x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Antikor Biopharma Limited Overview
Antikor Biopharma Limited is a live company located in northamptonshire, NN14 4LN with a Companies House number of 04170519. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in March 2001, it's largest shareholder is ironwood citadel (ptc) limited with a 36% stake. Antikor Biopharma Limited is a mature, small sized company, Pomanda has estimated its turnover at £1.1m with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Antikor Biopharma Limited Health Check
Pomanda's financial health check has awarded Antikor Biopharma Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
3 Strong
2 Regular
5 Weak
Size
annual sales of £1.1m, make it smaller than the average company (£3.7m)
- Antikor Biopharma Limited
£3.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 3%, show it is growing at a slower rate (4.4%)
- Antikor Biopharma Limited
4.4% - Industry AVG
Production
with a gross margin of 47%, this company has a comparable cost of product (47%)
- Antikor Biopharma Limited
47% - Industry AVG
Profitability
an operating margin of 148.7% make it more profitable than the average company (4%)
- Antikor Biopharma Limited
4% - Industry AVG
Employees
with 13 employees, this is below the industry average (46)
13 - Antikor Biopharma Limited
46 - Industry AVG
Pay Structure
on an average salary of £57.2k, the company has an equivalent pay structure (£57.2k)
- Antikor Biopharma Limited
£57.2k - Industry AVG
Efficiency
resulting in sales per employee of £84k, this is less efficient (£107.3k)
- Antikor Biopharma Limited
£107.3k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Antikor Biopharma Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 56 days, this is slower than average (47 days)
- Antikor Biopharma Limited
47 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Antikor Biopharma Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 23 weeks, this is less cash available to meet short term requirements (39 weeks)
23 weeks - Antikor Biopharma Limited
39 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 26.7%, this is a lower level of debt than the average (44.1%)
26.7% - Antikor Biopharma Limited
44.1% - Industry AVG
ANTIKOR BIOPHARMA LIMITED financials
Antikor Biopharma Limited's latest turnover from July 2023 is estimated at £1.1 million and the company has net assets of £8.3 million. According to their latest financial statements, Antikor Biopharma Limited has 13 employees and maintains cash reserves of £218.3 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | Jul 2013 | Jul 2012 | Jul 2011 | Jul 2010 | Jul 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 53,148 | 153,698 | 216,967 | 91,910 | 0 | 45,830 | 0 | 0 | |||||||
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||
| Cost Of Sales | 467,339 | 803,244 | 530,997 | 406,343 | 313,837 | 178,850 | 117,745 | ||||||||
| Gross Profit | -414,191 | -649,546 | -314,030 | -314,433 | -313,837 | -133,020 | -117,745 | ||||||||
| Admin Expenses | 242,446 | 347,040 | 153,764 | 105,773 | 99,674 | 96,026 | 70,130 | ||||||||
| Operating Profit | -656,637 | -996,586 | -467,794 | -420,206 | -413,511 | -229,046 | -187,875 | -136,776 | |||||||
| Interest Payable | 31,503 | 0 | 0 | 0 | 0 | 149 | 0 | 0 | |||||||
| Interest Receivable | 39 | 481 | 224 | 98 | 38 | 44 | 33 | 1,336 | |||||||
| Pre-Tax Profit | -688,101 | -996,105 | -467,570 | -420,108 | -413,473 | -229,002 | -187,842 | -135,440 | |||||||
| Tax | 144,435 | 83,625 | 29,534 | 16,067 | 0 | 29,794 | 0 | 0 | |||||||
| Profit After Tax | -543,666 | -912,480 | -438,036 | -404,041 | -413,473 | -199,208 | -187,842 | -135,440 | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Retained Profit | -543,666 | -912,480 | -438,036 | -404,041 | -413,473 | -199,208 | -187,842 | -135,440 | |||||||
| Employee Costs | 9,504 | 1,360 | |||||||||||||
| Number Of Employees | 13 | 11 | 12 | 12 | 9 | 8 | 8 | 12 | |||||||
| EBITDA* | -579,556 | -922,341 | -429,697 | -385,260 | -384,442 | -205,259 | -166,465 | -116,280 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | Jul 2013 | Jul 2012 | Jul 2011 | Jul 2010 | Jul 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 73,122 | 75,723 | 108,303 | 114,446 | 37,934 | 0 | 3,083 | 37,907 | 63,484 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 10,640,269 | 8,775,990 | 7,574,048 | 6,134,695 | 4,868,909 | 3,939,615 | 3,246,560 | 86,445 | 106,731 | 114,125 | 97,627 | 87,006 | 58,210 | 67,195 | 63,200 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 10,713,391 | 8,851,713 | 7,682,351 | 6,249,141 | 4,906,843 | 3,939,615 | 3,249,643 | 124,352 | 170,215 | 114,125 | 97,627 | 87,006 | 58,210 | 67,195 | 63,200 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 5,000 | 0 | 0 | 0 | 15,053 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50,181 | 52,264 | 0 | 11,667 | 0 |
| Misc Debtors | 394,426 | 522,493 | 239,921 | 293,735 | 321,097 | 28,183 | 43,634 | 5,372 | 96,936 | 309,613 | 42,646 | 659,489 | 1,761 | 20,018 | 3,439 |
| Cash | 218,252 | 341,951 | 132,905 | 105,653 | 240,422 | 164,693 | 129,893 | 18,431 | 178,161 | 294,529 | 203,193 | 5,268 | 32,842 | 153,096 | 76,418 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 612,678 | 864,444 | 372,826 | 399,388 | 561,519 | 197,876 | 173,527 | 23,803 | 275,097 | 619,195 | 296,020 | 717,021 | 34,603 | 184,781 | 79,857 |
| total assets | 11,326,069 | 9,716,157 | 8,055,177 | 6,648,529 | 5,468,362 | 4,137,491 | 3,423,170 | 148,155 | 445,312 | 733,320 | 393,647 | 804,027 | 92,813 | 251,976 | 143,057 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 89,264 | 80,012 | 105,944 | 100,249 | 162,549 | 59,171 | 107,058 | 24,077 | 104,964 | 4,303 | 3,432 | 2,660 | 4,306 | 2,660 | 11,044 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11,250 | 3,000 | 8,500 | 41,822 | 23,147 | 83,934 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 402,765 | 326,289 | 207,883 | 286,099 | 97,474 | 37,821 | 31,353 | 149,305 | 45,909 | 4,468 | 750 | 2,361 | 24,155 | 4,431 | 4,376 |
| total current liabilities | 492,029 | 406,301 | 313,827 | 386,348 | 260,023 | 96,992 | 138,411 | 173,382 | 150,873 | 20,021 | 7,182 | 13,521 | 70,283 | 30,238 | 99,354 |
| loans | 2,528,468 | 2,665,748 | 1,506,918 | 0 | 0 | 1,785,543 | 1,345,543 | 737,000 | 513,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 605,028 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 2,528,468 | 2,665,748 | 1,506,918 | 605,028 | 0 | 1,785,543 | 1,345,543 | 737,000 | 513,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 3,020,497 | 3,072,049 | 1,820,745 | 991,376 | 260,023 | 1,882,535 | 1,483,954 | 910,382 | 663,873 | 20,021 | 7,182 | 13,521 | 70,283 | 30,238 | 99,354 |
| net assets | 8,305,572 | 6,644,108 | 6,234,432 | 5,657,153 | 5,208,339 | 2,254,956 | 1,939,216 | -762,227 | -218,561 | 713,299 | 386,465 | 790,506 | 22,530 | 221,738 | 43,703 |
| total shareholders funds | 8,305,572 | 6,644,108 | 6,234,432 | 5,657,153 | 5,208,339 | 2,254,956 | 1,939,216 | -762,227 | -218,561 | 713,299 | 386,465 | 790,506 | 22,530 | 221,738 | 43,703 |
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | Jul 2013 | Jul 2012 | Jul 2011 | Jul 2010 | Jul 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -656,637 | -996,586 | -467,794 | -420,206 | -413,511 | -229,046 | -187,875 | -136,776 | |||||||
| Depreciation | 33,429 | 32,580 | 29,414 | 19,348 | 5,836 | 3,083 | 34,824 | 34,824 | 31,742 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amortisation | 33,994 | 44,522 | 36,933 | 26,393 | 29,806 | 36,595 | 39,239 | 42,257 | 42,503 | 38,097 | 34,946 | 29,069 | 23,787 | 21,410 | 20,496 |
| Tax | 144,435 | 83,625 | 29,534 | 16,067 | 0 | 29,794 | 0 | 0 | |||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -128,067 | 282,572 | -53,814 | -27,362 | 287,914 | -10,451 | 38,262 | -91,564 | -227,730 | 231,839 | -618,926 | 709,992 | -29,924 | 28,246 | 3,439 |
| Creditors | 9,252 | -25,932 | 5,695 | -62,300 | 103,378 | -47,887 | 82,981 | -80,887 | 100,661 | 871 | 772 | -1,646 | 1,646 | -8,384 | 11,044 |
| Accruals and Deferred Income | 76,476 | 118,406 | -78,216 | 188,625 | 59,653 | 6,468 | -117,952 | 103,396 | 41,441 | 3,718 | -1,611 | -21,794 | 19,724 | 55 | 4,376 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -321,048 | -468,884 | -627,413 | 248,894 | -1,117,874 | -124,171 | -203,040 | -104,299 | |||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -11,250 | 8,250 | -5,500 | -33,322 | 18,675 | -60,787 | 83,934 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | -137,280 | 1,158,830 | 1,506,918 | 0 | -1,785,543 | 440,000 | 608,543 | 224,000 | 513,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | -605,028 | 605,028 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | -31,464 | 481 | 224 | 98 | 38 | -105 | 33 | 1,336 | |||||||
| cash flow from financing | 192,536 | 482,851 | 773,344 | -5,402 | 1,148,165 | 18,570 | 305,123 | 264,413 | |||||||
| cash and cash equivalents | |||||||||||||||
| cash | -123,699 | 209,046 | 27,252 | -134,769 | 75,729 | 34,800 | 111,462 | -159,730 | -116,368 | 91,336 | 197,925 | -27,574 | -120,254 | 76,678 | 76,418 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -123,699 | 209,046 | 27,252 | -134,769 | 75,729 | 34,800 | 111,462 | -159,730 | -116,368 | 91,336 | 197,925 | -27,574 | -120,254 | 76,678 | 76,418 |
antikor biopharma limited Credit Report and Business Information
Antikor Biopharma Limited Competitor Analysis
Perform a competitor analysis for antikor biopharma limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in NN14 area or any other competitors across 12 key performance metrics.
antikor biopharma limited Ownership
ANTIKOR BIOPHARMA LIMITED group structure
Antikor Biopharma Limited has no subsidiary companies.
Ultimate parent company
PERPETUAL HOLDINGS LTD
#0108527
1 parent
ANTIKOR BIOPHARMA LIMITED
04170519
antikor biopharma limited directors
Antikor Biopharma Limited currently has 4 directors. The longest serving directors include Dr Till Medinger (Apr 2001) and Dr Mahendra Deonarain (Sep 2005).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Till Medinger | 84 years | Apr 2001 | - | Director | |
| Dr Mahendra Deonarain | 58 years | Sep 2005 | - | Director | |
| Mr Hian Ngiam | Hong Kong | 40 years | Jan 2019 | - | Director |
| Mr Joseph O'Sullivan | 54 years | May 2023 | - | Director |
P&L
July 2023turnover
1.1m
+16%
operating profit
1.6m
0%
gross margin
47%
-0.85%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
July 2023net assets
8.3m
+0.25%
total assets
11.3m
+0.17%
cash
218.3k
-0.36%
net assets
Total assets minus all liabilities
antikor biopharma limited company details
company number
04170519
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
March 2001
age
23
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
July 2023
previous names
photobiotics limited (July 2014)
choosespirit limited (April 2001)
accountant
-
auditor
-
address
montague house chancery lane, thrapston, northamptonshire, NN14 4LN
Bank
-
Legal Advisor
-
antikor biopharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to antikor biopharma limited.
antikor biopharma limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ANTIKOR BIOPHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.
antikor biopharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
